Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BTIG Upgrades Globus Medical to Buy, Announces $60 Price Target

Author: Benzinga Newsdesk | March 18, 2024 08:06am
BTIG analyst Ryan Zimmerman upgrades Globus Medical (NYSE:GMED) from Neutral to Buy and announces $60 price target.

Posted In: GMED